Commission acts on CHMP Esmya advice
Executive Summary
The European Commission has “opened the way” for Gedeon Richter to relaunch in European markets the Esmya (ulipristal acetate) women’s healthcare brand, after adopting an opinion from the CHMP recommending measures to minimise the risk of rare but serious liver injury.
You may also be interested in...
EMA Safety Panel Recommends Withdrawing Esmya Authorizations
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the European Medicines Agency’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
EMA Safety Commission Recommends Withdrawal Of Esmya Authorizations
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the EMA’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch
With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.